Prenetics Global Limited (NASDAQ: PRE) Stock Competitors & Peer Comparison
See PRE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRE | $19.75 | +0.25% | 335.8M | -9.59 | -$2.06 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $588.29 | -1.28% | 218.5B | 25.39 | $23.16 | +0.30% |
| DHR | $202.45 | -0.71% | 142.3B | 25.37 | $7.98 | +0.71% |
| NTRA | $309.93 | -0.27% | 44.4B | -194.92 | -$1.59 | N/A |
| IDXX | $550.96 | -2.82% | 43.5B | 38.75 | $14.22 | N/A |
| A | $148.53 | -0.51% | 42B | 25.57 | $5.81 | +0.68% |
| IQV | $236.66 | -2.01% | 39B | 19.52 | $12.13 | N/A |
| WAT | $412.17 | -0.32% | 30.8B | 30.12 | $13.68 | N/A |
| ILMN | $190.89 | -0.91% | 28.9B | 37.95 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
PRE vs DHR-PB Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PRE's ROE is -0.47%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for PRE.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
PRE vs TMO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, TMO has a market cap of 218.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while TMO trades at $588.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas TMO's P/E ratio is 25.39. In terms of profitability, PRE's ROE is -0.47%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PRE is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for PRE.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
PRE vs DHR Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DHR has a market cap of 142.3B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DHR trades at $202.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DHR's P/E ratio is 25.37. In terms of profitability, PRE's ROE is -0.47%, compared to DHR's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for PRE.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
PRE vs NTRA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NTRA has a market cap of 44.4B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NTRA trades at $309.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NTRA's P/E ratio is -194.92. In terms of profitability, PRE's ROE is -0.47%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, PRE is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for PRE.Check NTRA's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
PRE vs IDXX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, IDXX has a market cap of 43.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while IDXX trades at $550.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas IDXX's P/E ratio is 38.75. In terms of profitability, PRE's ROE is -0.47%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, PRE is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for PRE.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
PRE vs A Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, A has a market cap of 42B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while A trades at $148.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas A's P/E ratio is 25.57. In terms of profitability, PRE's ROE is -0.47%, compared to A's ROE of +0.21%. Regarding short-term risk, PRE is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for PRE.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
PRE vs IQV Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, IQV has a market cap of 39B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while IQV trades at $236.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas IQV's P/E ratio is 19.52. In terms of profitability, PRE's ROE is -0.47%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PRE is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for PRE.Check IQV's competition here
Waters Corporation (NYSE: WAT)
PRE vs WAT Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, WAT has a market cap of 30.8B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while WAT trades at $412.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas WAT's P/E ratio is 30.12. In terms of profitability, PRE's ROE is -0.47%, compared to WAT's ROE of +0.02%. Regarding short-term risk, PRE is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for PRE.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
PRE vs ILMN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ILMN has a market cap of 28.9B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ILMN trades at $190.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ILMN's P/E ratio is 37.95. In terms of profitability, PRE's ROE is -0.47%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, PRE is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for PRE.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
PRE vs MTD Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MTD has a market cap of 28.7B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MTD trades at $1,419.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MTD's P/E ratio is 32.61. In terms of profitability, PRE's ROE is -0.47%, compared to MTD's ROE of -12.00%. Regarding short-term risk, PRE is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for PRE.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
PRE vs LH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, LH has a market cap of 26.1B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while LH trades at $318.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas LH's P/E ratio is 18.87. In terms of profitability, PRE's ROE is -0.47%, compared to LH's ROE of +0.12%. Regarding short-term risk, PRE is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for PRE.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
PRE vs DGX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DGX trades at $234.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DGX's P/E ratio is 23.29. In terms of profitability, PRE's ROE is -0.47%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PRE is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for PRE.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
PRE vs GH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, GH has a market cap of 21.1B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while GH trades at $157.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas GH's P/E ratio is -60.93. In terms of profitability, PRE's ROE is -0.47%, compared to GH's ROE of +2.11%. Regarding short-term risk, PRE is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for PRE.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
PRE vs EXAS Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PRE's ROE is -0.47%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, PRE is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for PRE.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
PRE vs ILMNV Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ILMNV's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to ILMNV's ROE of N/A. Regarding short-term risk, PRE is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for PRE.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
PRE vs MEDP Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MEDP trades at $578.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MEDP's P/E ratio is 33.91. In terms of profitability, PRE's ROE is -0.47%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, PRE is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for PRE.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
PRE vs PKI Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PKI's P/E ratio is 41.45. In terms of profitability, PRE's ROE is -0.47%, compared to PKI's ROE of +0.03%. Regarding short-term risk, PRE is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for PRE.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
PRE vs CRL Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CRL has a market cap of 13.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CRL trades at $280.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CRL's P/E ratio is 28.29. In terms of profitability, PRE's ROE is -0.47%, compared to CRL's ROE of -0.08%. Regarding short-term risk, PRE is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for PRE.Check CRL's competition here
Revvity, Inc. (NYSE: RVTY)
PRE vs RVTY Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, RVTY has a market cap of 13B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while RVTY trades at $116.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas RVTY's P/E ratio is 21.83. In terms of profitability, PRE's ROE is -0.47%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PRE is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for PRE.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
PRE vs ICLR Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ICLR trades at $163.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ICLR's P/E ratio is 13.31. In terms of profitability, PRE's ROE is -0.47%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, PRE is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for PRE.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
PRE vs QGEN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, QGEN has a market cap of 8.9B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while QGEN trades at $42.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas QGEN's P/E ratio is 17.76. In terms of profitability, PRE's ROE is -0.47%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PRE is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for PRE.Check QGEN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PRE vs TWST Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, TWST has a market cap of 7.4B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while TWST trades at $118.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas TWST's P/E ratio is -53.41. In terms of profitability, PRE's ROE is -0.47%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PRE is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PRE.Check TWST's competition here
RadNet, Inc. (NASDAQ: RDNT)
PRE vs RDNT Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while RDNT trades at $76.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas RDNT's P/E ratio is 165.98. In terms of profitability, PRE's ROE is -0.47%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PRE is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for PRE.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
PRE vs SHC Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while SHC trades at $18.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas SHC's P/E ratio is 19.68. In terms of profitability, PRE's ROE is -0.47%, compared to SHC's ROE of +0.27%. Regarding short-term risk, PRE is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for PRE.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
PRE vs SYNH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PRE's ROE is -0.47%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for PRE.Check SYNH's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
PRE vs BLLN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BLLN has a market cap of 4.3B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BLLN trades at $93.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BLLN's P/E ratio is 133.33. In terms of profitability, PRE's ROE is -0.47%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for PRE.Check BLLN's competition here
Veracyte, Inc. (NASDAQ: VCYT)
PRE vs VCYT Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while VCYT trades at $41.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas VCYT's P/E ratio is 20.63. In terms of profitability, PRE's ROE is -0.47%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, PRE is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for PRE.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
PRE vs OLK Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas OLK's P/E ratio is -96.59. In terms of profitability, PRE's ROE is -0.47%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PRE is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for PRE.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
PRE vs NEOG Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NEOG trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NEOG's P/E ratio is 41.61. In terms of profitability, PRE's ROE is -0.47%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PRE is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for PRE.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
PRE vs CDNA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CDNA trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CDNA's P/E ratio is 53.95. In terms of profitability, PRE's ROE is -0.47%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, PRE is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for PRE.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
PRE vs PSNL Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PSNL has a market cap of 1.5B. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PSNL trades at $14.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PSNL's P/E ratio is -12.88. In terms of profitability, PRE's ROE is -0.47%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, PRE is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for PRE.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
PRE vs CSTL Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CSTL has a market cap of 933.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CSTL trades at $29.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CSTL's P/E ratio is -69.43. In terms of profitability, PRE's ROE is -0.47%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, PRE is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for PRE.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
PRE vs GRALV Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas GRALV's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to GRALV's ROE of N/A. Regarding short-term risk, PRE is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for PRE.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
PRE vs FLGT Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, FLGT has a market cap of 527.1M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while FLGT trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas FLGT's P/E ratio is 1856.00. In terms of profitability, PRE's ROE is -0.47%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, PRE is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for PRE.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
PRE vs NEO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NEO has a market cap of 409.6M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NEO trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NEO's P/E ratio is 122.62. In terms of profitability, PRE's ROE is -0.47%, compared to NEO's ROE of -0.06%. Regarding short-term risk, PRE is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for PRE.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
PRE vs CO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CO's P/E ratio is 5.06. In terms of profitability, PRE's ROE is -0.47%, compared to CO's ROE of +0.11%. Regarding short-term risk, PRE is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for PRE.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
PRE vs FLDM Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PRE's ROE is -0.47%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, PRE is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for PRE.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
PRE vs MYGN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MYGN has a market cap of 286.2M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MYGN trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MYGN's P/E ratio is -23.31. In terms of profitability, PRE's ROE is -0.47%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, PRE is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for PRE.Check MYGN's competition here
Prenetics Global Limited (NASDAQ: PRENW)
PRE vs PRENW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PRENW has a market cap of 262.7M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PRENW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, PRE is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check PRENW's competition here
Trinity Biotech plc (NASDAQ: TRIB)
PRE vs TRIB Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, TRIB has a market cap of 236.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while TRIB trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas TRIB's P/E ratio is -0.19. In terms of profitability, PRE's ROE is -0.47%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, PRE is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for PRE.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
PRE vs BDSX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BDSX has a market cap of 195.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BDSX trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BDSX's P/E ratio is -7.57. In terms of profitability, PRE's ROE is -0.47%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, PRE is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for PRE.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
PRE vs XGN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, XGN has a market cap of 160.9M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while XGN trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas XGN's P/E ratio is -9.65. In terms of profitability, PRE's ROE is -0.47%, compared to XGN's ROE of -1.22%. Regarding short-term risk, PRE is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for PRE.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
PRE vs IMDX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, IMDX has a market cap of 139.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while IMDX trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas IMDX's P/E ratio is -3.63. In terms of profitability, PRE's ROE is -0.47%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, PRE is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for PRE.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
PRE vs GTH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas GTH's P/E ratio is -1.11. In terms of profitability, PRE's ROE is -0.47%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PRE is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for PRE.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
PRE vs GENE Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas GENE's P/E ratio is -38.25. In terms of profitability, PRE's ROE is -0.47%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PRE is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for PRE.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
PRE vs SERA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, SERA has a market cap of 74.9M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while SERA trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas SERA's P/E ratio is -3.02. In terms of profitability, PRE's ROE is -0.47%, compared to SERA's ROE of -0.47%. Regarding short-term risk, PRE is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for PRE.Check SERA's competition here
Atlantic International Corp. (NASDAQ: ATLN)
PRE vs ATLN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ATLN's P/E ratio is -0.68. In terms of profitability, PRE's ROE is -0.47%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, PRE is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for PRE.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
PRE vs DRIO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DRIO has a market cap of 53.6M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DRIO trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DRIO's P/E ratio is -1.25. In terms of profitability, PRE's ROE is -0.47%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, PRE is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for PRE.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
PRE vs PRPO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PRPO has a market cap of 41.9M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PRPO trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PRPO's P/E ratio is -90.38. In terms of profitability, PRE's ROE is -0.47%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, PRE is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for PRE.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
PRE vs MDXH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MDXH has a market cap of 41.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MDXH trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MDXH's P/E ratio is -2.13. In terms of profitability, PRE's ROE is -0.47%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, PRE is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for PRE.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
PRE vs QUCY Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, QUCY has a market cap of 33.6M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while QUCY trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas QUCY's P/E ratio is -0.07. In terms of profitability, PRE's ROE is -0.47%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, PRE is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for PRE.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
PRE vs AKU Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas AKU's P/E ratio is -0.13. In terms of profitability, PRE's ROE is -0.47%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PRE is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for PRE.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
PRE vs CEMI Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PRE's ROE is -0.47%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PRE is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for PRE.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
PRE vs ENZ Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PRE's ROE is -0.47%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, PRE is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for PRE.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
PRE vs PMD Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PMD's P/E ratio is -5.24. In terms of profitability, PRE's ROE is -0.47%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PRE is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for PRE.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
PRE vs ME Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ME's P/E ratio is -0.03. In terms of profitability, PRE's ROE is -0.47%, compared to ME's ROE of -42.03%. Regarding short-term risk, PRE is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for PRE.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
PRE vs MYNZ Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, PRE's ROE is -0.47%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, PRE is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for PRE.Check MYNZ's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
PRE vs BNGO Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BNGO trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BNGO's P/E ratio is -0.27. In terms of profitability, PRE's ROE is -0.47%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, PRE is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for PRE.Check BNGO's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
PRE vs ADVB Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ADVB has a market cap of 12.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ADVB trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ADVB's P/E ratio is -81.36. In terms of profitability, PRE's ROE is -0.47%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, PRE is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for PRE.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
PRE vs CHEK Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CHEK's P/E ratio is -0.43. In terms of profitability, PRE's ROE is -0.47%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PRE is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for PRE.Check CHEK's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
PRE vs BNR Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BNR has a market cap of 9.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BNR trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BNR's P/E ratio is -11.00. In terms of profitability, PRE's ROE is -0.47%, compared to BNR's ROE of -0.11%. Regarding short-term risk, PRE is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for PRE.Check BNR's competition here
Centogene N.V. (NASDAQ: CNTG)
PRE vs CNTG Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PRE's ROE is -0.47%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PRE is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for PRE.Check CNTG's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
PRE vs MBAI Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MBAI has a market cap of 8.7M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MBAI trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MBAI's P/E ratio is 13.01. In terms of profitability, PRE's ROE is -0.47%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, PRE is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for PRE.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
PRE vs APDN Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas APDN's P/E ratio is -0.10. In terms of profitability, PRE's ROE is -0.47%, compared to APDN's ROE of -7.23%. Regarding short-term risk, PRE is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for PRE.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
PRE vs NDRA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NDRA has a market cap of 5.7M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NDRA trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NDRA's P/E ratio is -0.57. In terms of profitability, PRE's ROE is -0.47%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, PRE is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for PRE.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
PRE vs NVTA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PRE's ROE is -0.47%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PRE is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for PRE.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
PRE vs LMDXW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PRE's ROE is -0.47%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PRE is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
PRE vs LMDX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.47%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PRE is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for PRE.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
PRE vs DMTK Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PRE's ROE is -0.47%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PRE is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for PRE.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
PRE vs NOTV Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NOTV's P/E ratio is -0.03. In terms of profitability, PRE's ROE is -0.47%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, PRE is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for PRE.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
PRE vs BIAF Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BIAF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BIAF's P/E ratio is -0.05. In terms of profitability, PRE's ROE is -0.47%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, PRE is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for PRE.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
PRE vs SQL Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas SQL's P/E ratio is -0.40. In terms of profitability, PRE's ROE is -0.47%, compared to SQL's ROE of +38.02%. Regarding short-term risk, PRE is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for PRE.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
PRE vs AWH Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas AWH's P/E ratio is -0.09. In terms of profitability, PRE's ROE is -0.47%, compared to AWH's ROE of +2.03%. Regarding short-term risk, PRE is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for PRE.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
PRE vs INBS Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, INBS has a market cap of 1.8M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while INBS trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas INBS's P/E ratio is -0.33. In terms of profitability, PRE's ROE is -0.47%, compared to INBS's ROE of -1.74%. Regarding short-term risk, PRE is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for PRE.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
PRE vs HTGM Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PRE's ROE is -0.47%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PRE is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for PRE.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
PRE vs BIOC Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.47%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PRE is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for PRE.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
PRE vs ISPC Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, ISPC has a market cap of 312.4K. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while ISPC trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas ISPC's P/E ratio is -0.07. In terms of profitability, PRE's ROE is -0.47%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, PRE is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for PRE.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
PRE vs SQLLW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, PRE's ROE is -0.47%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, PRE is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check SQLLW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
PRE vs NDRAW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, PRE is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check NDRAW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
PRE vs OCDX Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PRE's ROE is -0.47%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PRE is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for PRE.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
PRE vs PRXL Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas PRXL's P/E ratio is 42.97. In terms of profitability, PRE's ROE is -0.47%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, PRE is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for PRE.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
PRE vs DHR-PA Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PRE's ROE is -0.47%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for PRE.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
PRE vs MEUSW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, PRE is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
PRE vs BNGOW Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, PRE is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for PRE.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
PRE vs CHEKZ Comparison August 2026
Prenetics Global Limited (NASDAQ: PRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 335.8M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PRE is priced at $19.75 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -9.59, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.47%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, PRE is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for PRE.Check CHEKZ's competition here